RAS Dialogue Blog
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
RAS InsightDavid Heimbrook, now CEO of the Frederick National Laboratory for Cancer Research, played a major role in a large pharma as it tried to develop an anti-RAS drug. Lessons from that failure inform the RAS Initiative today.
-
The RAS Reference Reagents Program: Sharing Resources and Enabling RAS ResearchDominic Esposito describes how the preparation of highly qualified reagents for use in the RAS Initiative also supports research in the broader RAS community
-
More Evidence That a Wild-Type KRAS Allele Plays a Role in CancerJim Hartley of the RAS Initiative discusses evidence from mouse models that a wild type KRAS allele modulates early selection of Q61L or Q61R mutants in lung cancers.
-
Ras Mitogenic Signaling: p53 Enters the StageMariano Barbacid and Matthias Drosten describe experiments that reveal a new role for the p53/p21Clp1/Rb axis in controling MAPK signaling.
-
Targeting Ras Membrane Association: Still an Achilles HeelMark Philips reviews attempts to drug KRAS, and to influence its translocation to the plasma membrane.